Loading clinical trials...
Loading clinical trials...
The purpose of this study is to test a new drug, RG2417, to see how the drug affects symptoms of bipolar I depression and to make sure it is safe in humans.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Repligen Corporation
NCT03336918 · Bipolar Disorder, Bipolar I Depression, and more
NCT05227209 · Depressive Episodes, Bipolar I Depression
NCT05169710 · Depressive Episodes, Bipolar I Depression
NCT01403662 · Bipolar Disorder, Bipolar Depression, and more
Birmingham Psychiatry Pharmaceutical Studies, Inc.
Birmingham, Alabama
K&S Professional Research Services
Little Rock, Arkansas
Affiliated Research Institute
San Diego, California
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions